Keck School Faculty

Welmoed Kirsten van Deen, MD
Welmoed Kirsten van Deen, MD
Assistant Professor Of Clinical Medicine
Medicine
GNH 1937 Hospital Place Off Campus Los Angeles
Dr. van Deen's major areas of research interest are value-based healthcare implementation and outcome and utilization measurement. She is currently a member of the International Consortium for Health Outcomes Measurement (ICHOM) IBD Standard Set Working Group.

Dr. van Deen earned her medical degree from Leiden University Medical Center. She then returned to complete her PhD in Medicine a few years later.

American Gastroenterological Association: Digestive Disease Week Poster of Distinction Award, 2015

Leiden University, The Netherlands: LUSTRA Travel Scholarship, 2011

Using insurance claims to predict and improve hospitalizations and biologics use in members with inflammatory bowel diseases J Biomed Inform. 2018 May; 81:93-101. . View in PubMed

Developing a Standard Set of Patient-Centred Outcomes for Inflammatory Bowel Disease-an International, Cross-disciplinary Consensus J Crohns Colitis. 2018 Mar 28; 12(4):408-418. . View in PubMed

The impact of value-based healthcare for inflammatory bowel diseases on healthcare utilization: a pilot study Eur J Gastroenterol Hepatol. 2017 Mar; 29(3):331-337. . View in PubMed

Value redefined for inflammatory bowel disease patients: a choice-based conjoint analysis of patients' preferences Qual Life Res. 2017 02; 26(2):455-465. . View in PubMed

Development and Validation of an Inflammatory Bowel Diseases Monitoring Index for Use With Mobile Health TechnologiesClin Gastroenterol Hepatol. 2016 Dec; 14(12):1742-1750. e7. . View in PubMed

Optimization of human mesenchymal stem cell manufacturing: the effects of animal/xeno-free media Sci Rep. 2015 Nov 13; 5:16570. . View in PubMed

MicroRNA214 Is Associated With Progression of Ulcerative Colitis, and Inhibition Reduces Development of Colitis and Colitis-Associated Cancer in MiceGastroenterology. 2015 Oct; 149(4):981-92. e11. . View in PubMed

Presenteeism in Inflammatory Bowel Diseases: A Hidden Problem with Significant Economic Impact Inflamm Bowel Dis. 2015 Jul; 21(7):1623-30. . View in PubMed

Value-based health care for inflammatory bowel diseases J Crohns Colitis. 2015 May; 9(5):421-7. . View in PubMed

A nationwide 2010-2012 analysis of US. health care utilization in inflammatory bowel diseases. Inflamm Bowel Dis. 2014 Oct; 20(10):1747-53. . View in PubMed

Anti-TNF antibodies in inflammatory bowel disease: do we finally know how it works? Curr Drug Targets. 2013 Nov; 14(12):1421-32.. View in PubMed

IBD: Antibodies to anti-TNF therapy--consequences for IBD management Nat Rev Gastroenterol Hepatol. 2013 Aug; 10(8):446-8. . View in PubMed

Stem cell therapy in inflammatory bowel disease: which, when and how? Curr Opin Gastroenterol. 2013 Jul; 29(4):384-90.. View in PubMed

Mucosal schwann cell hamartoma in ulcerative colitis: diagnosis and clinical relevance Gastroenterol Hepatol (N Y). 2013 Mar; 9(3):185-6. . View in PubMed

Immunomodulatory effects of mesenchymal stromal cells in Crohn's disease J Allergy (Cairo). 2012; 2012:187408. . View in PubMed

Powered by SC CTSI
Go to Top